What medications are used to manage delirium-induced agitation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Delirium-Induced Agitation

Non-pharmacological interventions should be implemented first for all patients with delirium-induced agitation, with pharmacological management reserved for patients with significant distress from hallucinations/delusions or severe agitation that poses risk to themselves or others. 1

First-Line Approach: Non-Pharmacological Interventions

  • Implement multicomponent interventions including reorientation, cognitive stimulation, use of clocks and calendars, optimizing sleep, reducing unnecessary sedation, early mobilization, and ensuring access to hearing aids and glasses if needed 1, 2
  • Provide ongoing educational programs for healthcare professionals regarding delirium management 2
  • Identify and manage underlying medical contributors to delirium through comprehensive evaluation 1, 2
  • Optimize pain management, preferably with non-opioid medications, to prevent worsening delirium 2
  • Avoid medications with high risk for precipitating or worsening delirium 2

Pharmacological Management for Severe Agitation

When non-pharmacological approaches are insufficient for managing severe agitation:

Antipsychotics

  • Antipsychotics should not be used routinely but may be considered for short-term use in patients with significant distress or severe agitation 2, 1
  • Use the lowest effective dose for the shortest possible duration 2, 1
  • Options include:
    • Haloperidol: 0.5-2 mg PO/IV/IM (reduce dose in older adults) 2, 3
    • Olanzapine: 2.5-5 mg PO/IM (sedating effect may be beneficial in hyperactive delirium) 2
    • Quetiapine: 25-50 mg PO (less likely to cause extrapyramidal symptoms) 2
    • Risperidone: 0.5 mg PO (available as orally disintegrating tablet) 2
    • Aripiprazole: 5 mg PO/IM (less likely to cause extrapyramidal symptoms) 2

Special Situations

  • Dexmedetomidine is recommended for mechanically ventilated patients with agitation preventing weaning/extubation 2, 4
  • For alcohol or benzodiazepine withdrawal-induced delirium, benzodiazepines are the treatment of choice 2

Benzodiazepines

  • Benzodiazepines should not be used as first-line treatment of agitation associated with delirium 2, 1
  • May be considered as crisis medication for severe agitation when other approaches fail 2
  • Options in severe cases:
    • Midazolam: 0.5-2.5 mg SC/IV (lower doses in older/frail patients) 2
    • Lorazepam: 0.25-1 mg SC/IV/PO (can cause paradoxical agitation) 2

Important Clinical Considerations

  • Discontinue all antipsychotic agents immediately following resolution of distressing symptoms 2, 1
  • Monitor for adverse effects of antipsychotics, particularly extrapyramidal symptoms with higher doses of haloperidol 5, 3
  • Low-dose haloperidol appears to be as effective as and safer than higher doses in older adults 3
  • Antipsychotics and benzodiazepines should be avoided for treatment of hypoactive delirium 2
  • Cholinesterase inhibitors should not be newly prescribed to prevent or treat postoperative delirium 2
  • Atypical antipsychotics (olanzapine, risperidone, quetiapine) may have similar efficacy to haloperidol with potentially fewer extrapyramidal side effects 5, 2

Monitoring and Reassessment

  • Regularly assess response to interventions using validated delirium assessment tools 4
  • Evaluate the need for continued medication daily 4
  • Continue to address underlying causes of delirium while managing symptoms 1
  • Monitor for sedation, which increases with higher doses of antipsychotics 3

References

Guideline

Management of Agitated Delirium

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Agitation in Mechanically Ventilated Patients with Schizophrenia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Antipsychotics for delirium.

The Cochrane database of systematic reviews, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.